Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

• Status: Recruiting
• Trial end date: 2026-09-12
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virtuoso BINco, Inc.

Criteria

Inclusion Criteria:

• Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease

• Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated.

• Adequate kidney, liver, and hematologic function

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria:

• Active brain metastases and history of leptomeningeal metastases.

• Myeloma patients with plasmacytoma as only measurable disease

• Non-secretory myeloma

• Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications

• Active or chronic, uncontrolled bacterial, viral, or fungal infection(s)

• Abnormal ECG

• Has clinically significant cardiovascular disease

• Additional active malignancy that may confound the assessment of the study endpoints

• Pregnancy or lactation

• Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C